Insider · CIK 0001134657
EVNIN LUKE
Reports to the SEC for 47 companies · BOSTON, MA
Transactions
50
Companies
47
Filings
9
CIK
0001134657
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-07-07 | HOWLWerewolf Therapeutics, Inc.S Sale | −$33.3K |
| 2026-07-06 | HOWLWerewolf Therapeutics, Inc.S Sale | −$11.4K |
| 2026-06-29 | HOWLWerewolf Therapeutics, Inc.S Sale | −$47.1K |
| 2026-06-09 | HOWLWerewolf Therapeutics, Inc.S Sale | −$28.5K |
| 2026-06-08 | HOWLWerewolf Therapeutics, Inc.S Sale | −$24.2K |
| 2026-06-05 | HOWLWerewolf Therapeutics, Inc.S Sale | −$9,978.4 |
| 2026-06-04 | HOWLWerewolf Therapeutics, Inc.S Sale | −$8,831.68 |
| 2026-06-03 | HOWLWerewolf Therapeutics, Inc.S Sale | −$12.5K |
| 2026-06-02 | HOWLWerewolf Therapeutics, Inc.S Sale | −$13.3K |
| 2026-06-01 | HOWLWerewolf Therapeutics, Inc.S Sale | −$37.8K |
| 2026-05-29 | HOWLWerewolf Therapeutics, Inc.S Sale | −$14.7K |
| 2026-05-28 | HOWLWerewolf Therapeutics, Inc.S Sale | −$12.7K |
| 2026-05-27 | HOWLWerewolf Therapeutics, Inc.S Sale | −$38.8K |
| 2026-05-26 | HOWLWerewolf Therapeutics, Inc.S Sale | −$31.9K |
| 2026-05-22 | HOWLWerewolf Therapeutics, Inc.S Sale | −$39.3K |
| 2026-05-21 | HOWLWerewolf Therapeutics, Inc.S Sale | −$15.3K |
| 2026-05-20 | HOWLWerewolf Therapeutics, Inc.S Sale | −$36.9K |
| 2026-05-19 | HOWLWerewolf Therapeutics, Inc.S Sale | −$28.3K |
| 2026-05-18 | HOWLWerewolf Therapeutics, Inc.S Sale | −$11.1K |
| 2026-05-13 | HOWLWerewolf Therapeutics, Inc.S Sale | −$24.1K |
| 2026-05-12 | HOWLWerewolf Therapeutics, Inc.S Sale | −$43.4K |
| 2026-05-11 | HOWLWerewolf Therapeutics, Inc.S Sale | −$22.7K |
| 2026-05-08 | HOWLWerewolf Therapeutics, Inc.S Sale | −$214K |
| 2026-05-07 | HOWLWerewolf Therapeutics, Inc.S Sale | −$49.8K |
| 2026-05-06 | HOWLWerewolf Therapeutics, Inc.S Sale | −$9,659.1 |
| 2026-05-05 | HOWLWerewolf Therapeutics, Inc.S Sale | −$4,733.4 |
| 2026-05-04 | HOWLWerewolf Therapeutics, Inc.S Sale | −$34.5K |
| 2026-05-01 | HOWLWerewolf Therapeutics, Inc.S Sale | −$42.6K |
| 2026-04-30 | HOWLWerewolf Therapeutics, Inc.S Sale | −$121K |
| 2026-04-29 | HOWLWerewolf Therapeutics, Inc.S Sale | −$39K |
| 2026-04-28 | HOWLWerewolf Therapeutics, Inc.S Sale | −$69.7K |
| 2026-04-27 | HOWLWerewolf Therapeutics, Inc.S Sale | −$45.8K |
| 2026-01-16 | HOWLWerewolf Therapeutics, Inc.S Sale | −$20.9K |
| 2026-01-15 | HOWLWerewolf Therapeutics, Inc.S Sale | −$20.6K |
| 2026-01-14 | HOWLWerewolf Therapeutics, Inc.S Sale | −$17.5K |
| 2026-01-13 | HOWLWerewolf Therapeutics, Inc.S Sale | −$23.8K |
| 2026-01-12 | HOWLWerewolf Therapeutics, Inc.S Sale | −$33.6K |
| 2026-01-09 | HOWLWerewolf Therapeutics, Inc.S Sale | −$15.1K |
| 2026-01-08 | HOWLWerewolf Therapeutics, Inc.S Sale | −$4,861.08 |
| 2026-01-07 | HOWLWerewolf Therapeutics, Inc.S Sale | −$7,625.6 |
| 2026-01-06 | HOWLWerewolf Therapeutics, Inc.S Sale | −$26.5K |
| 2026-01-05 | HOWLWerewolf Therapeutics, Inc.S Sale | −$11.8K |
| 2026-01-02 | HOWLWerewolf Therapeutics, Inc.S Sale | −$11.7K |
| 2025-12-31 | HOWLWerewolf Therapeutics, Inc.S Sale | −$15.5K |
| 2025-12-30 | HOWLWerewolf Therapeutics, Inc.S Sale | −$21.3K |
| 2025-12-29 | HOWLWerewolf Therapeutics, Inc.S Sale | −$66.2K |
| 2025-12-26 | HOWLWerewolf Therapeutics, Inc.S Sale | −$22.4K |
| 2025-12-24 | HOWLWerewolf Therapeutics, Inc.S Sale | −$10.6K |
| 2025-12-23 | HOWLWerewolf Therapeutics, Inc.S Sale | −$45K |
| 2025-12-22 | HOWLWerewolf Therapeutics, Inc.S Sale | −$40.9K |
Recent filings
- 4EVNIN LUKE0001134657-26-000020SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000019SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000018SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000017SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000016SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000015SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000014SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000012SEC(opens sec.gov)
- 4EVNIN LUKE0001134657-26-000011SEC(opens sec.gov)
Companies
- Acorda Therapeutics, Inc.10% Owner
- Aktis Oncology, Inc.10% OwnerAKTS
- Altimmune, Inc.10% OwnerALT
- ALUS Liquidation Corp10% Owner
- ARATANA THERAPEUTICS, INC.10% Owner
- ARYx Therapeutics, Inc.10% Owner
- Avalo Therapeutics, Inc.10% OwnerAVTX
- AVEO PHARMACEUTICALS, INC.Former 10% Stockholder
- BARRIER THERAPEUTICS INC10% Owner
- CHIASMA, INC10% Owner
- CORNERSTONE THERAPEUTICS INC10% Owner
- COTHERIX INC10% Owner
- CRYOCOR INC10% Owner
- Dyne Therapeutics, Inc.10% OwnerDYN
- Entrada Therapeutics, Inc.10% OwnerTRDA
- EPIRUS Biopharmaceuticals, Inc.10% Owner
- Epizyme, Inc.10% Owner
- Harpoon Therapeutics, Inc.Former 10% Owner
- HELICOS BIOSCIENCES CORP10% Owner
- HEMOSENSE INC10% Owner
- Histogen Inc.10% Owner
- HUMANIGEN, INC10% Owner
- IPASS INC10% Owner
- iTeos Therapeutics, Inc.Former 10% Owner
- MEMORY PHARMACEUTICALS CORP10% Owner
- METABASIS THERAPEUTICS INCDirector, 10% Owner
- Oncorus, Inc.Director
- OSCIENT PHARMACEUTICALS CORP10% Owner
- Pacira BioSciences, Inc.DirectorPCRX
- PEPLIN INC10% Owner
- Pernix Sleep, Inc.10% Owner
- Pharmasset IncFormer 10% Owner
- PONIARD PHARMACEUTICALS, INC.10% Owner
- Radius Health, Inc.Former 10% stockholder
- Repare Therapeutics Inc.10% OwnerRPTX
- ReShape Weightloss Inc.Director
- RHYTHM PHARMACEUTICALS, INC.10% OwnerRYTM
- RIGEL PHARMACEUTICALS INC10% OwnerRIGL
- SENORX INC10% Owner
- Syndax Pharmaceuticals IncDirector, 10% OwnerSNDX
- TCR2 THERAPEUTICS INC.10% Owner
- TERCICA INC10% Owner
- T-Mobile US, Inc.10% OwnerTMUS
- TURMERIC ACQUISITION CORP.Chief Executive Officer
- Verastem, Inc.Former 10% stockholderVSTM
- VIACELL INC10% Owner
- Werewolf Therapeutics, Inc.DirectorHOWL
Address
C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100
BOSTON, MA, 02116